{Reference Type}: Journal Article
{Title}: Long-acting injectable buprenorphine in the real world: case report on dual disorders.
{Author}: Palma-Alvarez RF;Ortega-Hernández G;Roch-Santed M;Ramos-Quiroga JA;Grau-López L;
{Journal}: J Addict Dis
{Volume}: 0
{Issue}: 0
{Year}: 2024 May 21
{Factor}: 2.065
{DOI}: 10.1080/10550887.2024.2354566
{Abstract}: <B>UNASSIGNED: </B>Long-acting injectable buprenorphine (LAIB) has demonstrated a good profile for opioid use disorder (OUD) management. However, there is scarce information on LAIB in OUD patients with comorbid mental disorders (dual disorder patients).<BR><B>UNASSIGNED: </B>We present a case report on OUD patients with a comorbid mental disorder who have received LAIB for at least 3 months.<BR><B>UNASSIGNED: </B>Two women and one man with OUD and another comorbid mental disorder were prescribed with LAIB ranging from three to twelve months. Good adherence and opioid abstinence were observed during the follow-up. Psychopathological issues related to comorbid mental disorders were stabilized. A deep discussion on LAIB in this profile of patients is conducted.<BR><B>UNASSIGNED: </B>LAIB in OUD patients with comorbid mental disorders may be a safe and well tolerated option, similar to OUD patients without comorbid mental disorders. LAIB's impact on psychopathological issues requires further high-quality research to understand the real impact of LAIB on OUD and comorbid mental disorders.